Pregnancy and Lactation Labeling
The U.S. Food and Drug Administration (FDA) is proposing major revisions to prescription drug labeling to provide more complete information about the effects of medicines used during pregnancy and breast-feeding. The proposed changes to physician labeling would give healthcare providers better information for making prescribing decisions and for counseling women who are pregnant, breast-feeding, or of child-bearing age.
FDA proposes that the pregnancy and lactation subsections of labeling include a risk summary, which summarizes the risks of the medicine to the developing baby (fetus) or breast-feeding infant, and a discussion of the data supporting that summary. The labeling would also include relevant clinical information useful for counseling pregnant or lactating women about medications, and prescribing and managing use of those medications.
The proposal would eliminate the current pregnancy categories A, B, C, D, and X. The “Labor and Delivery” subsection would be eliminated because information on labor and delivery would be included in the “Pregnancy” subsection. The proposed rule is intended to create a consistent format for providing information about the risks and benefits of medicine use during pregnancy and lactation. In doing so, the proposed rule would enhance well-informed decision making by healthcare practitioners and women of childbearing age.
Back to Top
Back to Regulatory Information
PDF requires the free
Adobe Acrobat Reader
Date created: May 28, 2008, updated June 11, 2008